United Kingdom

People: Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.83 (+3.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Grossi, Federico 

Mr. Federico Grossi M.D. Ph.D., is Chief Medical Officer of the Company. Dr. Grossi has served as our Chief Medical Officer since April 2019, having served as our Executive Vice President of Clinical Development from October 2017 until April 2019, our Vice President of Clinical Development from October 2014 to October 2017 and as our Clinical Research Director from April 2010 to June 2012. Dr. Grossi served as Executive Vice President of Potentia from October 2013 to September 2014, and as Clinical Research Director of Potentia from 2006 to April 2010. From June 2012 to October 2014, Dr. Grossi worked as an independent early stage clinical research consultant. Dr. Grossi received his M.D. from the University of Córdoba in Argentina and his Ph.D. in physiology from the University of Louisville. Following his post-graduate training in surgery, where he developed his expertise in microsurgery and composite tissue transplantation, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville.

Basic Compensation

Total Annual Compensation, USD 494,516
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,264,960
Fiscal Year Total, USD 2,759,480

Options Compensation

  Quantity Market Value
Exercisable 273,001 --
Unexercisable -- --
Exercised 14,750 --